Wire · regulatory
FDA seeks feedback on quantitative medicine network
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 August 2026 · Fusion42 review
The FDA is soliciting stakeholder feedback to develop a Quantitative Medicine Innovation Network (QMIN) aimed at accelerating drug development and regulatory science through collaborative quantitative medicine approaches. The initiative seeks input on collaboration mechanisms, priority focus areas, and operational models to enhance drug development and clinical decision-making.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You will need to engage with the FDA's new Quantitative Medicine Innovation Network early to shape priorities and make your computational models part of drug development pathways. This opens a direct channel to influence regulatory acceptance and speed to market.
◆ Coverage
1 source · 4 Aug 2026
◆ Related on Wire
◆ Topics